Glacial Gold is the #1 selling CBD forward vape in British Columbia

Nextleaf has become the #2 supplier of CBD oils in British Columbia

Vancouver, British Columbia–(Newsfile Corp. – April 20, 2022) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf“, or the “Company“), a federally regulated manufacturer and distributor of cannabis vapes and oils, announced today it has completed its initial shipment of Glacial Gold vapes and distilled oils to the Ontario Cannabis Store (“OCS“), and provided an update on its cannabis sales in British Columbia (“B.C.“).

Wholly-owned by the Province of Ontario, the OCS is the sole distributor in the province and all Ontario cannabis retailers must purchase their inventory through the OCS. Vapes and distilled oils under the Company’s award-winning prohibition-era brand, Glacial Gold will be available at retail stores across Ontario and at osc.ca in early May 2022.

“Shipping our initial order to the OCS is a major milestone as we look forward to growing our relationship with the provincial distributor by delighting consumers in Ontario the way we have delighted consumers in B.C. with quality products at accessible price points,” said Nextleaf CEO and co-founder Paul Pedersen.

British Columbia Market¹

Glacial Gold continues to see strong consumer demand and sell-through during the brand’s initial six months in the British Columbia market. Nextleaf is pleased to provide the following key metrics in B.C. for the quarter ended March 31, 2022:

• Nextleaf is a top-10 supplier of vapes and oils
• Glacial Gold Anytime 1:1 is the #1 selling CBD forward vape SKU
• Glacial Gold is the #2 brand in CBD & balanced oils by revenue
• Glacial Gold is the #6 brand in 1-gram vapes by revenue
• 44% increase in market share quarter-over-quarter in the oil category
• 14% increase in market share quarter-over-quarter in the vape category
• Glacial Gold has seven SKUs in the 1-gram vape sub-category, second amongst all brands

Glacial Gold continues to outsell the largest brands in Canada in the key categories of vapes and CBD oils. During Q1 2022, Nextleaf sold more vapes and oils in B.C. than Canopy Growth, Tilray Brands, Aurora Cannabis, The Valens Company, Medipharm Labs, Sundial Growers, and TerrAscend. “Nextleaf’s patented technology has enabled Glacial Gold to outperform some of the largest regulated cannabis companies in the world in vapes and CBD oils,” said Pedersen.

Nextleaf has been issued 10 U.S. patents for what it believes to be the most efficient technology to produce high-purity cannabinoid distillate in a regulated market.

Glacial Gold Display at Kiaro in Port Moody, British Columbia

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/5347/120991_7714b59b14af0b40_001full.jpg

Learn more at www.Glacial.Gold

Nextleaf Issues Shares and Options

Nextleaf has issued an aggregate of 866,741 common shares at a deemed price of $0.135 per share to scientific and technical consultants of the Company, as compensation for services provided.

The Company has awarded non-executive employees of the Company options to purchase up to 70,000 common shares of the Company pursuant to the Company’s Stock Option Plan, exercisable at a price of $0.175 per share.

The Company has issued 500,000 warrants to purchase common shares of the Company to the holder of the convertible note issued on March 31, 2021 (the “Note”). The warrants were issued as consideration for revision of terms of the Note, and are exercisable at a price of $0.162 per share for a period of 36 months from the date of issuance.

About Nextleaf®

Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold. The Company’s multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplier of THC and CBD ingredients to qualified wholesale partners across Canada. Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial extraction and purification of cannabinoids. The Company has been issued 18 U.S. patents, and over 90 patents globally, on cannabinoid processing including distillation and acetylation. Nextleaf develops proprietary cannabinoid-based formulations and delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. For more information visit www.nextleafsolutions.com and www.Glacial.Gold

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.

Follow Glacial Gold: Instagram, Twitter, and Facebook.

Jason McBride, Corporate Development
604-283-2301 (ext. 219)
[email protected]

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, receipt of the Dealer’s Licence within the anticipated timeframe or at all, the activities the Company expects to conduct if the Dealer’s Licence, the ability of the Company to develop and protect intellectual property relating to psychedelics, the expected benefits to the Company if the Dealer’s Licence is received, the Dealer’s License assisting the company in obtaining a unique position for the Company to develop a suite of standardized plant-derived drugs, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

¹ British Columbia market share according to BC Cannabis Wholesale sales data (January – March 2022).

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.

“These mushrooms are an important milestone in Optimi’s commitment to establishing a supply of safe, natural psilocybin products for use by approved parties engaged in clinical trials,” said Optimi Health CEO Bill Ciprick. “Since the completion of our 20,000 square foot cultivation and processing facilities and the approval of our Controlled Drugs and Substances Dealers License by Health Canada, Optimi has pressed forward with the goal of generating revenue and demonstrating a system of safe supply that can scale with the needs of the sector while participating in research crucial to the advancement of psychedelic science.”

The initial batch of Optimi’s natural psilocybin mushrooms is intended specifically for analysis and use in human clinical trials where market demand for natural psilocybin is increasing.

Optimi is involved in a partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary and has opted to assess its product prior to completion of the Company’s clinical trial application.

Optimi has received a Section 56 Exemption to the Controlled Drugs and Substances Act from Health Canada in order to carry out its own research at the premises of Calgary-based Bloom Psychedelic Therapy & Research Centre (“Bloom”), with a focus on determining a safe and effective standardized microdose of psilocybin for mental health conditions such as anxiety and depression.

Optimi Executive Chairman, JJ Wilson, adds that today’s announcement is a “momentum building” milestone that speaks to the Company’s goal of becoming a world supplier in the cultivation and formulation of natural psilocybin.

“The Optimi team is 100 per cent committed to helping the world deal with the concurrent crises of mental health and aging with safe, sustainable supplies of an organic product that has been used medicinally since time immemorial,” said Wilson. “We will share more about our mission and vision over the coming weeks and months; however, for now, we’ll go back to the lab where our goal is to produce the quality and scale needed to meet the global demand for natural psilocybin.”

Optimi plans to showcase its new GMP facility at a brand and media launch in May.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION SEE CONTACT:

Investor Relations

Email: [email protected]

Phone: +1 (778) 930-1321

Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Eden Empire Inc. (CSE: EDEN) (the “Company” or “Eden Empire”) is pleased to announce that it has received its Cannabis Retail Store License Authorization (the “License”) from the Liquor & Cannabis Regulation Branch (the “LCRB”) for its cannabis dispensary location at 30 Lakeshore Dr. NW in Salmon Arm, BC (the “Location”). The Company is also pleased to announce that it has entered into a debt settlement agreement ‎‎(the “Debt Settlement”) with an arm’s length services provider of the Company to settle certain ‎outstanding invoices and completed the closing for the acquisition of certain companies for an aggregate amount of CAD$235,000 (the “Outstanding Amount”).

Corporate Update

In full settlement and satisfaction of the Outstanding Amount, the Company has issued ‎‎4,700,000 common shares of the Company at a deemed price of $0.05 per common share (the ‎‎“Debt Shares”). The issuance of the Debt Shares is subject to approval by the Canadian ‎Securities Exchange. All Debt Shares issued in connection with the Debt Settlement are subject ‎to a statutory hold period of four months plus a day from the date of issuance of the Debt Shares ‎in accordance with applicable securities legislation.‎

This news release does not constitute an offer of securities for sale in the United States. The securities ‎being offered have not been, nor will they be, registered under the United States Securities Act of ‎‎1933, as amended, and such securities may not be offered or sold within the United States absent U.S. ‎registration or an applicable exemption from U.S. registration requirements.‎

For further information or should you have any questions, please feel free to email us at [email protected].

Gerry Trapasso, CEO

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

About Eden Empire

Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales. Eden Empire intends to expand its retail operations in Canada and to expand its business to cannabis cultivation, extraction and processing‎ and become a fully integrated cannabis product company in the United States.

Eden Empire has an award winning and established nationwide brand, including a substantial intellectual property portfolio, and a dedicated management team with extensive cannabis industry experience. Upon completion of Eden Empire’s currently intended acquisitions, and approval to operate its retail locations, the Company is expected to have a significant retail cannabis footprint in Canada and Michigan. Retail cannabis operations are an emerging sector with significant cash flow potential.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon” “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information include, but are not limited to, statements with respect to the gross proceeds anticipated to be received under the Third Tranche Private Placement; the future exercise of any Warrants issued under the Third Tranche Private Placement; the future price of the Company’s common shares on the CSE; the future exercise by the Company of its right to accelerate the Warrant Expiry Date; the approval of the CSE of the Third Tranche Private Placement; the Company’s future operations of retail cannabis stores in the United States and Canada; the Company expanding its business to cannabis cultivation, extraction and processing and becoming a fully integrated cannabis company in the United States; the completion of the Company’s currently intended acquisitions; the receipt of all necessary licenses and approvals to operate the Company’s retail locations; and the proposed future transactions Eden may undertake and their expected timing.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Eden Empire to control or predict, that may cause Eden Empire’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: Eden Empire may not obtain the requisite regulatory approvals and may not begin operating cannabis retail or cultivation and processing operations; that the actual use of proceeds may differ from those currently stated; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; currency fluctuations; regulatory restrictions and the possibility for changes in laws, rules, and regulations in the industry; liability, competition, loss of key employees and other related risks and uncertainties. Eden Empire does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• 15 locations operational across B.C, Ontario and Saskatchewan.
• $42.7M annual forecasted revenue for next fiscal year.
• Company has plans to increase the operational footprint to 18 stores after opening its seventh B.C location in Kelowna and the potential development locations in Ontario.

VANCOUVER, BC, Nov. 12, 2021 /CNW/ – Kiaro Holdings Corp. (TSXV: KO) (“Kiaro” or the “Company“) a Canadian cannabis retailer and distributor, is pleased to announce the opening of its latest retail location in Orleans, Ontario (Unit D002, 3838 Innes Road, Orleans, Ontario, K1W 0C8). The brand currently has 15 locations operational across B.C, Ontario and Saskatchewan.

“We continue to see the Kiaro brand grow across Canada, providing a best-in-class retail cannabis experience to each and every customer we serve. The continued increase in our retail footprint to a potential of 18 stores in early 2022 will drive us towards $42.7M in target revenue for the next fiscal year” stated Daniel Petrov, Chief Executive Officer of Kiaro.

After opening of Kiaro’s seventh B.C location in Kelowna later this year and the potential development locations in Ontario, the company plans to grow the operational footprint to 18 stores.

Kiaro Holdings Corp.

Based in Vancouver, British Columbia, Kiaro is an independent, omni-channel cannabis retailer and distributor. Through existing storefronts across British Columbia, Saskatchewan, and Ontario, and with the completion of the recent acquisition of Hemisphere Cannabis from Aegis Brands, Kiaro has 15 stores with another three expected in early 2022. This is in addition to its wholesale distribution division servicing Saskatchewan, and ecommerce sites in Canada, the US and Australia. Kiaro is driven to introduce new and experienced consumers to a lifelong exploration of cannabis. With more than 70 years of collective retail and wholesale focused experience, Kiaro’s leadership team has a proven track record of executing on acquisitions and financings, and moreover growing brands across North America. The Company plans to continue its growth trajectory through its consumer-centric retail, ecommerce, and wholesale distribution segments over the coming years.

Forward-Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Kiaro, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the use of proceeds of the Offering, overall growth of the Canadian cannabis market and retail opportunities, the award of new operating permits and licenses in various jurisdictions, the future trading price of the Common Shares, and the timing and amount of any dispositions of the Common Shares. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Kiaro’s control. These risks, uncertainties and assumptions include, but are not limited to, those described in filing statement of the Company dated September 29, 2020, a copy of which is available on SEDAR at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward looking information with respect to future expansion plans is subject to the qualification that management of Kiaro may decide, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Kiaro does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, visit investors.kiaro.com
For our most recent analyst report, click here

SOURCE Kiaro Holdings Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vernon, British Columbia–(Newsfile Corp. – October 5, 2021) – True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLAA) (“True Leaf” or the “Company”) has renewed and received new debt funding to advance the development of its planned Monashee Gateway Business Park in Lumby, British Columbia. The new funding enables the Company to install services to phase one of the development. The Company recently listed for sale six lots covering 7.8 acres of land valued at approximately $6.4 million in the Okanagan commercial real estate market. An additional 32 acres will be subdivided and developed in subsequent phases.

True Leaf will allocate the new funds to install water, sewer, power, and landscaping services for the phase one development. The remaining funds will be used to pay down the Company’s property taxes and allocated to an interest reserve and mortgage renewal fees – immediately strengthening the Company’s financial position.

To secure the new funding, True Leaf renewed and increased its first mortgage on its property with Canguard Mortgage Investment Corporation (the “New Mortgage”) on October 1, 2021. The New Mortgage is comprised of a 15-month term, $4,000,000 mortgage loan bearing interest at a fixed rate of 10% per annum (calculated monthly and payable monthly and not in advance). The maturity date is now January 31, 2023 (previously due on December 1, 2021). No principal payments prior to maturity, interest only. The New Mortgage is secured by the Company’s property in Lumby, British Columbia (the “Lumby Property”) and a first priority security interest in all of the Company’s present and after-acquired personal property. The New Mortgage replaces the current mortgage of $3,000,000 with Canguard Mortgage Investment Corporation. The New Mortgage is subject to certain customary financial covenants and the following provisions regarding the additional $1,000,000 (the “advance”):

• Six months interest reserve will be deducted from the advance and applied to the first six months of interest payments ($200,000 including the October 1, 2021 payment);
• 2% amendment and renewal fee ($80,000) is to be deducted from the advance;
• Outstanding property taxes are to be brought up to date ($400,000);
• The remaining balance ($320,000) is to be held in trust and advanced directly to the contractors for work completed to service the Company’s property development.

Phase one lot sales will significantly strengthen True Leaf’s financial position as the Company executes its strategic plan to become the leading processing and distribution services provider for craft cannabis producers in British Columbia. The Company’s 19,500 square foot craft cannabis facility will anchor the Monashee Gateway Business Park creating a diverse and vibrant economic hub in the heart of the North Okanagan.

True Leaf also has a second mortgage of $1,700,000 (the “Second Mortgage”) on the Lumby Property with a second priority security interest in all of the True Leaf Cannabis present and after-acquired personal property for a term of one-year payable December 12, 2021, bearing interest of 12%. The Company is current with the loan and intends to renegotiate or satisfy the second mortgage with the sale of one of the subdivided properties.

About the Company
True Leaf is a Licensed Producer of cannabis preparing to launch a program to provide path-to-market services for micro-cultivators. The program will operate from the Company’s 19,500 square foot facility in Lumby, British Columbia, and offer a full suite of in-house processing services to the craft cannabis community.

To learn more, visit www.trueleafbrands.com.

Investor Contact:

Darcy Bomford
Chief Executive Officer
[email protected]
1 (250) 275-6063

Media Inquiries: [email protected]

Cautionary and Forward-Looking Statements

This news release contains “forward-looking statements” including, among other things, statements relating to the completion and timing for the two-batch amendment from Health Canada, license to sell cannabis products in retail stores, and the expected market for craft cannabis products. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of True Leaf to be materially different from those expressed or implied by such forward-looking information, including but not limited to: whether or not the Company will successfully renegotiate or pay-out its Second Mortgage, whether or not the Company obtains a federal sales license from Health Canada, the impact of general business, economic, competitive, geopolitical, and social uncertainties; regulatory risks; and other risks related to the cannabis industry. Forward-looking statements in this press release are expressly qualified by this cautionary statement. The forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no obligations to update publicly or to revise any of the included forward-looking statements, whether because of new information, future events or otherwise, except as expressly required by applicable securities law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, Aug. 05, 2021 (GLOBE NEWSWIRE) — EDEN Empire Inc. (“EDEN” or the “Company”) (CSE:EDEN) is pleased to announce the opening of the first EDEN retail location in Vancouver, British Columbia located in East-Vancouver, through a Sub-License & Operating Agreement (the “Agreement”) via an arm’s-length third party. The store located at 4317 Fraser Street is operational and open to the public as of July 30, 2021.

Key Takeaways

• The Company launched its first EDEN branded store in British Columbia.
• Located at 4317 Fraser Street, this area is primarily residential and resides besides ample street parking.
• Sits just steps away from a: liquor store, heavily-trafficked bus stop, numerous adult-focused establishments.

Gerry Trapasso, CEO & Director commented “The launch of the first EDEN branded location in Vancouver signifies a momentous moment for EDEN. The Agreement creates great exposure for EDEN and shows the power behind the EDEN brand and its rigorous client services. Our Company has worked tirelessly to create relationships with vendors in an otherwise very difficult market to enter which allows for successful Agreement’s to operate. We are confident that the launch of EDEN’s street-style brand in the East-Van market will give the local neighbourhood something to talk about.”

For further information or should you have any questions, please feel free to contact us at [email protected] .

Gerry Trapasso, CEO

About Eden Empire

EDEN is in the business of investments and operations in the cannabis sector and engaging ‎in retail cannabis sales. EDEN intends to expand its retail operations in Canada and to ‎expand its business to cannabis cultivation, extraction and processing‎ and become a vertically ‎integrated cannabis product company in the United States. ‎

EDEN has an award winning and established nationwide brand, including a substantial ‎intellectual property portfolio, and a dedicated management team with extensive cannabis ‎industry experience. Upon completion of EDEN’s currently intended acquisitions, and approval to operate its retail locations, the Company is expected to have a significant retail cannabis footprint in Canada and Michigan. Retail cannabis operations are an emerging sector ‎with significant cash flow potential. ‎

This press release is not an offer of securities for sale in the United States, and the securities described in this press release may not be offered or sold in the United States absent registration or an exemption from registration. The securities have not been and will not be registered under the United States Securities Act of 1933.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary note regarding Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon” “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information include, but are not limited to, statements with respect to: the successful launch of EDEN’s first retail dispensary location in Winnipeg; the potential for EDEN to amass a greater customer base in the Winnipeg market; the future returns of cannabis sales in the City of Winnipeg; the success of EDEN’s roll out of is direct-to-customer delivery service; the potential for EDEN to amplify its brand and loyal following; the potential for the Company to expand its business to cannabis cultivation, extraction and processing‎ and become a fully integrated cannabis product company in Canada and the United States; the completion of the Company’s currently intended acquisitions and approvals to operate its retail locations; the potential for the Company to have a significant retail cannabis footprint in British Columbia; the receipt of approvals from regulators in British Columbia, Ontario, Manitoba and Michigan for licenses to operate cannabis retail stores; the future of the retail cannabis market generally and its cash flow potential; and proposed future transactions the Company may undertake and their expected timing.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: the Company may not obtain the requisite regulatory approvals to operate and may not begin operating cannabis retail or cultivation and processing operations in British Columbia, Ontario, Manitoba or Michigan; that the actual use of proceeds may differ from those currently stated; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; currency fluctuations; regulatory restrictions and the possibility for changes in laws, rules, and regulations in the industry; liability, competition, loss of key employees and other related risks and uncertainties. The Company does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Company putting renewed focus on Nevada and California with Canadian asset sold and letters of intent cancelled

Kelowna, British Columbia–(Newsfile Corp. – April 20, 2021) – Fiore Cannabis Ltd. (CSE: FIOR) (OTCQX: FIORF) (“Fiore” or the “Company”), a licensed multi-state cannabis cultivator, producer and retailer, today announced that it has terminated the Letter of Intent (“LOI”) signed with Indigenomix International dated April 8, 2020 and amended June 15, 2020 and June 30, 2020 and has signed a Memorandum of Understanding (“MOU”) with PECA Properties (“PECA”) to transfer ownership of Fiore’s Celista, British Columbia asset as well as sell the Company’s wholly owned subsidiaries, Marapharm Inc and Full Spectrum Medicinal Inc., in consideration for debt and liabilities associated with the purchasing stakeholders.

The Celista asset includes 40 acres of land, two constructed buildings and a late-stage Health Canada Licence to Cultivate application. The final transaction enables Fiore to clean up its balance sheet by eliminating approximately $4.8 million of long-term liabilities, including a mortgage and other obligations.

“We are very pleased to have completed the sale of the Celista asset as it does not fit with the company’s strategic direction,” said Erik Anderson, President and CEO of Fiore Cannabis. “The transaction further cleans up our balance sheet and will enable us to allocate additional funds to drive expansion in our key markets of Nevada and California. We continue to expand upon our operations in Las Vegas and the Coachella Valley and focus our energies on where we are generating revenues and profitability, producing top-quality cannabis products, and generating returns to investors.”

The Company continued its focus on assets that deliver strong revenue and margins in its key markets of Nevada and California by announcing the cancellation of two additional LOIs in British Columbia. This included an LOI to purchase a micro cultivation facility, Laughing Turtle Farms, dated October 6, 2020 and an LOI to purchase two retail cannabis locations from 1260474 BC Ltd. dated October 8, 2020.

Anderson noted, “We’re moving away from holding onto non-performing assets in British Columbia to focus tightly on growing our revenue-generating assets in the U.S. We have significant opportunities awaiting us in Nevada and California to expand our footprint and become more vertically integrated and that’s where our singular focus is at this time.”

About Fiore Cannabis

Fiore Cannabis Ltd. (CSE: FIOR) (OTCQX: FIORF) is a publicly traded company that has been investing in the development of medical and recreational cannabis products since 2014. Fiore has expanded its operating portfolio to include cultivation, production and retail offerings in our key North American legal jurisdictions of Nevada and California. For more information, please visit www.fiorecannabis.com.

For Further Information:
Erik Anderson, President and CEO
1-877-438-5448 Ext. 713
[email protected]

Forward-Looking Information:

This news release contains forward-looking statements or information that relate to our current expectations and views of future events, including in respect of the strategic goals of the Company, our future growth and expansion plans in the U.S., the impact of the sale of the Celista Asset on the Company’s balance sheet, the impact of the sale of the assets in respect of the Company’s future results, operations and performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate”, “objective”, “may”, “will”, “might”, “should”, “could”, “can”, “intend”, “expect”, “believe”, “estimate”, “predict”, “potential”, “plan”, “is designed to”, “project”, “continue”, or similar expressions suggest future outcomes or the negative thereof or similar variations. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such factors include, among others: the risks and uncertainties identified in the Company’s reports and filings with the applicable Canadian securities regulators, risks and uncertainties related to the judgement of management in relation to accounting issues resulting from the sale of the assets, risks and uncertainties related to the impact of the sale of the assets, the effects and outcomes of the proposed expansion plans in the U.S., changes to the legislative regime to which the Company is subject to, the cultivation, production and sale of cannabis products in Nevada and California, and the saleability of future harvests. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Wholly-Owned German Subsidiary Developed THC Testkits In-House to Help Pharmacists Identify Medical Cannabis

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that its wholly-owned subsidiary, Farmako GmbH (“Farmako”) – a GDP certified pharmaceutical wholesaler with a focus on the cannabinoid therapy – has begun supplying STADAPHARM GmbH (“STADAPHARM”) with its proprietary THC Testkits (the “THC Testkits”). The THC Testkits were developed and produced by Farmako in-house and will be supplied to STADAPHARM as a tool for pharmacists to detect THC and identify medical cannabis flowers and extracts in an easy, quick and cost-efficient way.

STADAPHARM, which is responsible for the Specialty Pharmaceuticals business within the STADA Group, will be entering the medical cannabis market in the second quarter of 2021. The company will launch its own THC-containing cannabis flower products and extracts and will also offer the THC Testkits, developed and produced by Farmako, along with its own products to pharmacists for the identity testing of medical cannabis.

“Katrin and everyone at Farmako continue to demonstrate their ingenuity and passion for the cannabis industry in Germany. I am very proud of the team and commend their efforts to develop the THC Testkit in-house, obtain patent protection, bring it to market and secure the supply agreement with STADAPHARM,” said Elise Coppens, Chief Executive Officer and Director of AgraFlora.

“Discussion in the German cannabis market often circles around the high barriers for patients, suppliers, doctors and pharmacists. Therefore, we as Farmako want to facilitate easier access to cannabinoid therapy for patients with a high burden of suffering via fair prices, reliable supply and efficient service for healthcare professionals. For us, cooperation is an important element of competition, only in this way can we develop the market for the benefit of patients. Therefore, we are very happy about this partnership with STADAPHARM, a highly renowned pharma corporation,” commented Katrin Eckmans, CEO of Farmako GmbH.

Farmako has been supplying THC Testkits to pharmacies since December 2020. The THC Testkit, for which Farmako holds patent protection, facilitates identity testing of cannabis in only five minutes, without the need for further auxiliary devices or expensive reference substances – thus offering a better alternative to the time-consuming and costly thin layer chromatography method of identity testing pharmaceutical ingredients or medicines containing THC. Further, the THC Testkit has been validated by the German testing laboratory DSI-pharm, Quality Services International GmbH, regarding its specificity for the purpose of identifying cannabis flowers and extracts according to German Pharmacopoeia.

Farmako has been active as reliable supplier of medical cannabis flowers since beginning of 2019. In Q4 2020 the product portfolio was enhanced by pharma-grade CBD isolate (GMP) as well as the THC TestKit and IMC cannabis flowers. In the second quarter of 2021, Farmako will further complement its product range by offering its own high THC cannabis extracts at a fair price. In this way, Farmako takes root as a supplier with a comprehensive portfolio in the medical cannabis market and continues to present itself as reliable partner for the retail and wholesale market.

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a leading cannabis company building shareholder value through the development of revenue generating operating assets in the global cannabis industry. AgraFlora is focused primarily on the Canadian cannabis industry – the world’s most advanced and regulated legal cannabis market. Its flagship Canadian asset is Propagation Services Canada, a large-scale commercial greenhouse in Delta, BC focused on reshaping the Canadian flower market with high-potency, low-cost cannabis. In addition, AgraFlora’s wholly-owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active distribution operations in Germany and expects to commence active operations in the United Kingdom in 2021. For more information about AgraFlora, please visit agraflora.ca and its profile page on SEDAR at www.sedar.com.

ON BEHALF OF THE BOARD OF DIRECTORS
Nick Kuzyk, Investor Relations
E: [email protected]
T: (800) 783-6056

For French inquiries:
Maricom Inc.
Remy Scalabrini
E: [email protected]
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement
Except for statements of historic fact this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan” “expect” “project” “intend” “believe” “anticipate” “estimate” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including but not limited to delays or uncertainties with regulatory approvals including that of the CSE. There are uncertainties inherent in forward-looking information including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators which are available at www.sedar.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

RED DEER, AB, April 6, 2021 /CNW/ – Stigma Grow (“Stigma” or the “Company”) and its parent company, CanadaBis Capital Inc. (TSXV: CANB), are thrilled to announce they have entered into a third-party production agreement (the “Agreement”) with Sundial Growers Inc. (NASDAQ: SNDL) (“Sundial” or the “Company”), a Health Canada licensed cannabis producer recognized for its ‘small-batch-at-scale’ individualized ‘room’ approach, to produce a variety of Sundial’s hydrocarbon (BHO) concentrates.

Among other opportunities within the concentrates market, the new collaboration between the two Alberta-based companies will enable capitalization on the fast-emerging live-resin vape market.

Under the terms of the Agreement, Sundial will provide its input for both fresh-frozen and cured formats to Stigma to produce a variety of live-resin and cured cannabis concentrates.

Sundial expects to launch the products across Canada under the Top Leaf brand in Q3 2021.

“As one of the first-to-market producers of true live-resin, high-terpene, full-spectrum vape cartridges in Alberta we reviewed many partnership requests from some of legal cannabis’ most recognizable brands, but none provided the brand and business fit demonstrated by Sundial,” said Travis McIntyre, CEO of Stigma. “We look forward to working with this well-established Alberta brand long into the future and recognize the value that comes to those who partner strategically with like-minded visionaries.”

“As part of our continued focus within the premium inhalable segment, we are pleased to enter into a concentrates partnership with Stigma,” added Andrew Stordeur, President and Chief Operating Officer of Sundial.  “We believe this collaboration will provide our consumers with an excellent addition to our portfolio of cannabis products.”

In addition to this partnership announcement, the first two months of 2021 has seen the Company’s existing and new products accepted into Ontario, British Columbia, Manitoba and Saskatchewan, as education surrounding the quality and experience offered by live-resin concentrates makes its way across the country to millions of recreational and medicinal consumers typically looking for something new and improved.

About CanadaBis Capital Inc. & Stigma Grow

CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the global cannabis market – with specific attention paid to supplying the fast-emerging concentrates category through their Stigma Grow cultivation and extraction facility.

Acting as the cornerstone for everything they offer, Stigma Grow continuously strives to address the market demands and lingering stigmas within the legal cannabis industry head-on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada’s legal cannabis industry.

About Sundial Growers Inc. 

Sundial is a public company with Common Shares traded on Nasdaq under the symbol “SNDL”.

Sundial is a licensed producer that crafts cannabis using state-of-the-art indoor facilities. Our ‘craft-at-scale’ modular growing approach, award-winning genetics and experienced growers set us apart.

Our Canadian operations cultivate small-batch cannabis using an individualized “room” approach, with 448,000 square feet of total available space.

Sundial’s brand portfolio includes Top Leaf, Sundial Cannabis, Palmetto and Grasslands. Our consumer-packaged goods experience enables us to not just grow quality cannabis, but also to create exceptional consumer and customer experiences.

We are proudly Albertan, headquartered in Calgary, AB, with operations in Olds, AB, and Rocky View County, AB.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include but are not limited to statements with respect to our business and operations; timing of the Sundial products coming to market; the demand and market for live-resin vape cartridges, and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company’s products to compete with the pricing and product availability on the black-market; the market demand for the Company’s products; and assumptions concerning the Company’s competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company’s continuous disclosure on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE CanadaBis Capital Inc.

For further information: For more information on CanadaBis Capital or Stigma Grow visit: www.canadabis.com, www.stigmagrow.ca, or contact: Investor Relations [email protected] 1-888-STIGMA1

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.